Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
2015: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2016 - 2015 - 2014 - 2013

July 2015 Scleroderma News

Apricus Biosciences Announces Last Patient Enrolled in RayVa(TM) Phase 2a Clinical Trial for Raynaud's Phenomenon in Patients With Scleroderma. The company expects to report top-line data in the third quarter of 2015 in advance of potentially moving RayVa into a pivotal Phase 2b trial following further guidance discussions with the FDA. GlobeNewswire, 06/15/2015. (Also see Raynaud's Research)

Borderline Pulmonary Pressure in Scleroderma Patients Linked to a Pre-Pulmonary Arterial Hypertension Condition. A review study recently published suggests that borderline pulmonary pressure in patients with scleroderma can represent a condition of pre-pulmonary arterial hypertension (PAH). Scleroderma News, 06/01/2015. (Also see Pulmonary Hypertension Diagnosis)

Autoantibodies Present in Scleroderma, Myositis Explored in New Review. These specific autoantibodies play a role in muscle damage, their detection in an early disease stage may help predict the disease course and prognosis. Scleroderma News, 05/27/2015. (Also see Autoantibodies)

Viagra Reveals Benefits in Treating Digital Ulcers in Systemic Sclerosis. It was concluded that sildenafil seems to have a clinical benefit in digital ulcer healing in patients with systemic sclerosis. Scleroderma News, 05/26/2015. (Also see Treatments for Digital Ulcers)

Telangiectasia as a potential clinical marker of microvascular lesions in systemic sclerosis (SSc) patients from EUSTAR data in China. Telangiectasia are common in Chinese SSc patients and usually associated with digital ulcers, Raynaudís phenomenon, pulmonary artery hypertension and could be a clinical marker of microvascular disease in SSc. PubMed, Clin Exp Rheumatol, 05/25/2015. (Also see Telangiectasia)

Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. Harmonized definitions and measurement of clinically significant fatigue will advance research and clinical management of fatigue in rheumatic diseases and other conditions. PubMed, J Rheumatol, 06/01/2015. (Also see Breast Cancer and Fatigue)

In situ evidence of pulmonary endothelial activation in patients with granulomatosis with polyangiitis (GPA) and systemic sclerosis (SSc). These observations are an evidence of in situ pulmonary vascular endothelial activation in lesions of GPA and SScl, adding information to the pathogenic knowledge of both diseases. PubMed, Lung, 2015 Jun;193(3):355-9. (Also see Wegener's Granulomatosis)

Effects and safety of rituximab (RTX) in systemic sclerosis (SSC): an analysis from the European Scleroderma Trial and Research (EUSTAR) group. The comparison of RTX treated versus untreated matched-control SSc patients from the EUSTAR cohort demonstrated improvement of skin fibrosis and prevention of worsening lung fibrosis. PubMed, Ann Rheum Dis, 2015 Jun;74(6):1188-94. (Also see Biologic Agents)

Efficacy of sildenafil on ischaemic digital ulcer (DU) healing in systemic sclerosis: the placebo-controlled SEDUCE study. A significant decrease in the number of DUs in favour of sildenafil compared with placebo confirming a sildenafil benefit. PubMed, Ann Rheum Dis, 05/20/2015. (Also see Raynaud's Treatments: Medications)

Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review. Mycophenolate-associated gastrointestinal adverse events are common in SSc, but not severe enough to preclude its use and it may be effective in improving or stabilizing interstitial lung disease and skin involvement. PubMed, PLoS One, 2015 May 1;10(5):e0124205. (Also see Immunosuppressants)

A decision model for the watch-and-wait strategy in systemic sclerosis-associated interstitial lung disease (SSc-ILD). Watchful waiting may be effective for SSc-ILD patients who have minimal pulmonary involvement on CT and lack pulmonary arterial hypertension on echocardiography at baseline. PubMed, Rheumatology (Oxford), 05/13/2015. (Also see Pulmonary Fibrosis Treatments)

Go to Scleroderma Medical News: June 2015
Most Recent Donors

Winn Schillberg
Reading Voices of Scleroderma Books: Diana Kramer.
Sharing Scleroderma Awareness Bracelets: Deb Martin, Brenda Miller, Vickie Risner.
Thanks to UNITED WAY donors of Central New Mexico and Snohomish County!

In Loving Memory

Patricia Ann Black: Marilyn Currier, Shelley Ensz, Richard Howitt, Gerald and Pat Ivanejko, Juno Beach Condo Association, Keith and Rosalyn Miller, and Elaine Wible.
Gayle Hedlin: Daniel and Joann Pepper and Nancy Smithberg.
Janet Paulmenn: Anonymous, Mary Jo Austin, Shelley Blaser, Susan Book, Dennis and Pat Clayton, Grace Cunha, Cindy Dorio, Michael and Patricia Donahue, Shelley Ensz, Nancy Falkenhagen, Jo Frowde, Alice Gigl, Margaret Hollywood, Karen Khalaf and Family, Susan Kvarantan, Bradley Lawrence, Jillyan Little, Donna Madge, Michele Maxson, Barry and Judith McCabe, John Moffett, My Tribute Foundation, Joan-Marie Permison, John Roberts, Margaret Roof, Maryellen Ryan, Mayalin and Kiralee Murphy, Nancy Settle-Murphy, and Bruce and Elizabeth Winter.


SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA

Email [email protected] to request our Welcome email, or to report bad links or to update this page content.

TOLL FREE HOTLINE 800-564-7099
Free to U.S. and Canadian Callers. Ask for our Free Info Packet by mail or email!
Scleroderma, Pulmonary Arterial Hypertension, and related illnesses.
Privacy Policy.

The most important thing in the world to know about scleroderma is!
Donate Now
Copyright 1998-2016, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.